Product Description
Amino acid formulation for the dietary management of symptoms related to periphal neuropathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01537705)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Targeted Medical Pharma
Company Location: LOS ANGELES CA 90077
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01537705 |
Neuron012703 | P2 |
Unknown status |
Peripheral Nervous System Diseases |
2012-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|